Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

Figure 3

Clinical improvement of the Items contributing to the PedACR during 12 weeks of blinded treatment. (A) Physician's Global Assessment of disease activitry, (B) Parent's Global Assessment of overall well being, (C) Numbers of joints with active arthritis, (D) Childhood Health Assessment Questionnaire Disability Index, (E) joints with limited range of motion and serum levels of C-reactive Protein. The median is given. The global treatment difference was significant for physician's global assessment (P = 0.021), parents' global assessment (P = 0.016). At week 8 significant differences were noted for physician's global assessment (P = 0.006), parents' global assessment (P = 0.025), the number of active joints (P = 0.0007), the CHAQ-DI (P = 0.017).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us